Emc Capital Management Macrogenics Inc Transaction History

Emc Capital Management

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$8.12 - $16.9 $352,091 - $732,800	-43,361 Closed	0 $0
Q2 2021 Aug 09, 2021	BUY	$20.49 - $35.63 $174,021 - $302,605	8,493 Added 24.36%	43,361 $1.17 Million
Q1 2021 May 05, 2021	BUY	$18.99 - $33.2 $186,804 - $326,588	9,837 Added 39.3%	34,868 $1.11 Million
Q4 2020 Feb 24, 2021	BUY	$19.41 - $26.0 $485,851 - $650,806	25,031 New	25,031 $572,000

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $195M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Emc Capital Management, based on Form 13F filings with the SEC.

Stay updated on Emc Capital Management with notifications on news.